AGLE - アエグリア・バイオセラピュ―ティクス (Aeglea BioTherapeutics Inc.) アエグリア・バイオセラピュ―ティクス

 AGLEのチャート


 AGLEの企業情報

symbol AGLE
会社名 Aeglea BioTherapeutics Inc (アエグリア・バイオセラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Aeglea BioTherapeutics Inc. is a biotechnology company which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company''s product pipeline includes AEB1102 AEB3103 AEB2109 and AEB4104. Its lead product candidate AEB1102 is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism including arginine excess in patients with Arginase I deficiency an IEM as well as some cancers which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.   アエグリア・バイオセラピュ―ティクスは米国のバイオテクノロジ―企業。先天性の代謝疾患やがん治療のための治療用酵素の開発に注力する。血液中でアルギニン、システイン、メチオニン、ホモシステインなどの特定のアミノ酸を分解することで、がん疾患などにおける、アミノ酸の血中濃度を正常値に導くことに焦点を置く。本社はテキサス州オ―スティン。   Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families.
本社所在地 901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin TX 78746 USA
代表者氏名 Armen B. Shanafelt Armen B. Shanafelt
代表者役職名 Independent Chairman of the Board
電話番号 +1 512-942-2935
設立年月日 41609
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 43人
url www.aegleabio.com
nasdaq_url https://www.nasdaq.com/symbol/agle
adr_tso
EBITDA EBITDA(百万ドル) -32.25900
終値(lastsale) 9.63
時価総額(marketcap) 211812158.16
時価総額 時価総額(百万ドル) 209.99560
売上高 売上高(百万ドル) 6.63100
企業価値(EV) 企業価値(EV)(百万ドル) 137.80260
当期純利益 当期純利益(百万ドル) -31.89000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aeglea Bio Therapeutics Inc revenues increased 58% to $3.9M. Net loss increased 36% to $17.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 47% to $15.3M (expense) General and administrative - increase of 16% to $4.7M (expense).

 AGLEのテクニカル分析


 AGLEのニュース

   Why Aeglea BioTherapeutics Stock Is Way Down Today  2021/12/06 18:01:47 The Motley Fool
MIxed phase 3 clinical trial results are making investors nervous.
   Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency  2021/12/06 11:30:00 PR Newswire
AUSTIN, Texas, Dec. 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the pivotal Phase 3 study,
   -$0.29 EPS Expected for Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) This Quarter  2021/12/05 04:16:41 Transcript Daily
Brokerages expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to post ($0.29) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with the highest EPS estimate coming in at ($0.20) and the lowest estimate coming in at ($0.34). Aeglea BioTherapeutics reported earnings per share of []
   Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares Bought by Renaissance Technologies LLC  2021/11/26 09:36:42 Transcript Daily
Renaissance Technologies LLC grew its position in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 383.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,787 shares of the biotechnology companys stock after purchasing an additional 40,287 shares during the period. Renaissance Technologies LLC owned []
   Brokerages Expect Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Will Post Quarterly Sales of $3.07 Million  2021/11/22 23:32:41 Dakota Financial News
Analysts expect that Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) will announce sales of $3.07 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Aeglea BioTherapeutics earnings, with estimates ranging from $1.40 million to $6.41 million. The company is scheduled to issue its next earnings results on Thursday, March 17th. On []
   Aeglea BioTherapeutics (NASDAQ:AGLE) Earns Outperform Rating from Lifesci Capital  2021/11/06 12:58:42 Transcript Daily
Lifesci Capital reaffirmed their outperform rating on shares of Aeglea BioTherapeutics (NASDAQ:AGLE) in a report issued on Friday morning, Zacks.com reports. Other equities analysts have also issued reports about the company. Zacks Investment Research lowered Aeglea BioTherapeutics from a buy rating to a hold rating in a report on Thursday, August 12th. Evercore ISI initiated []
   Point72 Asset Management L.P. Trims Stock Position in Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE)  2021/11/04 12:08:42 Transcript Daily
Point72 Asset Management L.P. cut its stake in shares of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) by 68.7% during the second quarter, HoldingsChannel.com reports. The fund owned 469,765 shares of the biotechnology companys stock after selling 1,030,235 shares during the quarter. Point72 Asset Management L.P.s holdings in Aeglea BioTherapeutics were worth $3,270,000 at the end of the []
   Aeglea BioTherapeutics EPS misses by $0.01  2021/11/04 11:58:38 Seeking Alpha
   Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights  2021/11/04 11:01:00 PR Newswire
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third…
   Aeglea BioTherapeutics Announces Presentation of Seven Abstracts at ICIEM 2021 Including Oral Presentation of PEACE Study Baseline Characteristics  2021/11/04 10:59:00 Business Insider Markets
AUSTIN, Texas, Nov. 4, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that
   Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow  2021/09/10 18:05:21 Seeking Alpha
   Aeglea Biotherapeutics Inc (AGLE) CFO Jonathan Alspaugh Bought $262,822 of Shares  2021/08/19 18:15:05 GuruFocus
Related Stocks: AGLE ,
   Aeglea BioTherapeutics reports Q2 results  2021/08/05 13:13:43 Seeking Alpha
   Were Hedge Funds Right About Aeglea BioTherapeutics, Inc. (AGLE)?  2021/07/26 15:50:08 Insider Monkey
   Aeglea Biotherapeutics names Jonathan Alspaugh as chief financial officer  2021/07/08 12:37:01 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アエグリア・バイオセラピュ―ティクス AGLE Aeglea BioTherapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)